Natera stock slumps nearly 4% as profit-taking and technical resistance stall rally

Traders Union
All News
Stocks
Natera slides 3.79% today to $389.43

Highlights

Natera posted Q2 2026 revenue of $753 million, exceeding analyst consensus and reporting strong growth in test volume.
The Signatera molecular residual disease test gained wide adoption, robust scientific backing, and was named to TIME's Best Inventions of 2026.
Shares recently reached new highs but face near-term price pressure, with technical outlook mixed and a 5-day range projected at $376.79 to $414.34.

Strong fundamentals and positive news countered by insider selling pressure

Natera, Inc. reported Q2 2026 revenue of $753 million, surpassing consensus estimates. Its Signatera molecular residual disease test was named to TIME's Best Inventions of 2026 and has seen wide adoption and extensive scientific support. A proposed insider sale by Matthew Rabinowitz and a recent collaboration with TransCode were disclosed, with shares recently reaching new highs and revenue and test volume showing strong growth, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, questions the strength of Natera's current rally. He notes that despite impressive revenue and wide adoption of Signatera, the market is selling into good news. Technical signals are mixed, with the price failing to hold above short-term resistance and displaying volatility. Kharitonov points to the risk of further downside if momentum weakens and warns that recent insider selling casts doubt on sentiment. "Investors should remain cautious — the risk of a reversal remains high as profit-taking dominates despite positive headlines."

Viktoras Karapetjanc, expert at Traders Union, highlights Natera's strong business fundamentals. He sees the recent revenue beat and rapid adoption of Signatera as evidence of long-term value. The bullish technical structure suggests robust institutional interest and further growth potential. Karapetjanc expects positive sentiment to support higher prices if resistance is cleared. "The market offers multiple opportunities here — I see the bullish structure remaining intact and expect further gains if momentum resumes."

Sholanke Dele, market strategist, sees caution dominating in the near term. He points out that despite strong headlines, the sharp intraday drop and high volatility signal underlying risk. Dele is wary of short-term pressure as sellers take profits at new highs. "Right now, I think traders should defend capital — price action shows risk outweighs reward as the stock reacts poorly to good news."

Short-term weakness amid bullish structure as mixed signals emerge

Natera is trading below its 20-day moving average at $400.48, though it stays above the 50-day at $355.57 and the 200-day at $256.69, underscoring a bullish structure across medium and long-term timeframes. The Ichimoku Kijun at $379.18 acts as added support. Immediate technical levels are defined by a ceiling at $390.79 and a floor at $383.54. Momentum signals are mixed: the MACD shows a strong buy, and the ADX points to ongoing trend strength, but the RSI sits at a neutral 61.94. The Stochastic RSI is oversold at 18.9, flagging limited downside momentum; the CCI is neutral, and Bull/Bear Power remains positive at 10.78. However, the stock opened with an upside gap and is now near session lows after a steep drop, with intraday volatility at 5.08%. Near-term price action signals profit-taking and short-term pressure despite the overall bullish technical picture.

Previously it was reported that Natera’s strong technical momentum and business milestones supported a continued bullish outlook, despite broad selling pressure. The current article adds that while profit-taking has triggered short-term downside, the prevailing scenario remains sideways within the $376.79 to $414.34 volatility band, positioning a decisive move above $390.79 as the key level to watch for a potential bullish breakout.

Source of Data: NTRA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.